Dr. Stephen A. Besh, M.D.
Hematology & Oncology (Hematology & Oncology Physician)
At a glance
- Medical school
- Louisiana State University School of Medicine in New Orleans (1990)
- Years since graduation
- 36
- In the NPI registry since
- 2005
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1990Medical school: Louisiana State University School of Medicine in New Orleans
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
TN license 24886 · MS license 18531
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Methodist Hospitals of Memphis Memphis, TN
- Baptist Memorial Hospital Memphis, TN
- Magnolia Regional Health Center Corinth, MS
- Baptist Memorial Hospital Union County New Albany, MS
- Baptist Memorial Hospital Booneville Booneville, MS
Medical groups
- The West Clinic P.c. (118 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Payments from drug and device companies
In 2025, 20 companies reported 33 payments worth $720 in total to this clinician.
| Pfizer Inc. | $87.67 |
|---|---|
| Novartis Pharmaceuticals Corporation | $86.57 |
| Adaptive Biotechnologies Corporation | $62.21 |
| Gilead Sciences, Inc. | $48.46 |
| AstraZeneca Pharmaceuticals LP | $42.07 |
| Merck Sharp & Dohme LLC | $41.45 |
| E.r. Squibb & Sons, L.l.c. | $39.01 |
| Puma Biotechnology, Inc. | $35.55 |
| Food and Beverage | $720 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $3,960 in research payments for these studies, mostly to the institutions running them.
- A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
AbbVie Inc. · Recruiting · NCT04928846 - A phase 3b,randomized,multicenter,open label study to assess the efficacy of durvalumab plus tremelimumab versus pembrolizumab in combination with platinum based chemotherapy for first line treatment in mtastatic non …
AstraZeneca Pharmaceuticals LP
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.